<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221880</url>
  </required_header>
  <id_info>
    <org_study_id>ESP vs Lidocaine</org_study_id>
    <nct_id>NCT04221880</nct_id>
  </id_info>
  <brief_title>Erector Spinae Plane Block Versus Perioperative Intravenous Lidocaine for Thoracotomy</brief_title>
  <official_title>Erector Spinae Plane Block Versus Perioperative Intravenous Lidocaine for Postoperative Pain Control in Patients Undergoing Thoracotomy: A Prospective, Randomized, Double-blind Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ataturk University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thoracotomy surgery is the most painful of all surgical procedures. Inadequate postoperative
      pain control in these patients may cause serious morbidity related to pulmonary,
      cardiovascular and emotional systems. Erector Spinae Plane Block (ESPB) was first described
      in 2016 and, it is frequently used for postoperative analgesia in thoracic surgery.
      Intravenous lidocaine exhibit analgesic activity through both the peripheral and central
      nervous system. Intravenous lidocaine has been shown to reduce postoperative pain intensity
      and accelerate postoperative recovery in many surgeries.

      The investigators aimed to compare the effect of lidocaine infusion and erector spinae plane
      block on postoperative opioid consumption and pain scores.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>First 24 hours total opioid consumption</time_frame>
    <description>First 24 hours total fentanyl consumption with patient controlled analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog pain score</measure>
    <time_frame>Postoperative 24 hour</time_frame>
    <description>Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at first hour postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Thoracic Diseases</condition>
  <arm_group>
    <arm_group_label>Group ESPB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine and Saline iv. bolus and infusion (same volume as Group Lidocaine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion and, Ultrasound-guided erector spinae plane block with 20 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ultrasound-guided erector spinae plane block with 20 ml saline and, Saline iv. bolus and infusion (same volume as Group Lidocaine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hcl 0.25% Inj</intervention_name>
    <description>Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine</description>
    <arm_group_label>Group ESPB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution for Block</intervention_name>
    <description>Ultrasound-guided erector spinae plane block with 20 ml saline</description>
    <arm_group_label>Group Control</arm_group_label>
    <arm_group_label>Group Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution intravenously</intervention_name>
    <description>Same volume saline solution bolus and infusion as Group Lidocaine</description>
    <arm_group_label>Group Control</arm_group_label>
    <arm_group_label>Group ESPB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion</description>
    <arm_group_label>Group Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist's physiologic state I-III patients undergoing
             thoracotomy surgery

        Exclusion Criteria:

          -  chronic pain, bleeding disorders, renal or hepatic insufficiency, non cooperative
             patient,

          -  Patients with allergies to one of the drugs used in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elif Oral Ahiskalioglu, MD</last_name>
    <phone>00905059259632</phone>
    <email>drelforl@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuğberk Küçün, MD</last_name>
    <phone>00905373520716</phone>
    <email>tuberkkucun@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ataturk University</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmet Murat Yayik, MD</last_name>
      <phone>00905544259287</phone>
      <email>m_yayik@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Forero M, Rajarathinam M, Adhikary S, Chin KJ. Erector spinae plane (ESP) block in the management of post thoracotomy pain syndrome: A case series. Scand J Pain. 2017 Oct;17:325-329. doi: 10.1016/j.sjpain.2017.08.013. Epub 2017 Sep 12.</citation>
    <PMID>28919152</PMID>
  </reference>
  <reference>
    <citation>Moeen SM, Moeen AM. Usage of Intravenous Lidocaine Infusion with Enhanced Recovery Pathway in Patients Scheduled for Open Radical Cystectomy: A Randomized Trial. Pain Physician. 2019 Mar;22(2):E71-E80.</citation>
    <PMID>30921979</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk University</investigator_affiliation>
    <investigator_full_name>Ahmet Murat Yayik</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thoracic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

